# Irinotecan Liposomes Combined with Temozolomide and Vincristine in the Treatment of Pediatric Patients with Solid Tumors

> **NCT06710821** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Yizhuo Zhang** · enrollment: 40 (estimated)

## Conditions studied

- Solid Tumor Cancer

## Interventions

- **DRUG:** Liposomal irinotecan in combination with vincristine and temozolomide

## Key facts

- **NCT ID:** NCT06710821
- **Lead sponsor:** Yizhuo Zhang
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-12-01
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2024-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06710821

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06710821, "Irinotecan Liposomes Combined with Temozolomide and Vincristine in the Treatment of Pediatric Patients with Solid Tumors". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06710821. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*